GO
Loading...

Medicine

More

  • Carl Icahn: Can He Come To Amylin's Rescue? Monday, 17 Nov 2008 | 11:09 AM ET
    Carl Icahn

    Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals. The shares have plummeted from nearly $30 just three months ago to around $7 today.

  • Merck's Marketing Challenge: Gardasil For Guys Thursday, 13 Nov 2008 | 4:16 PM ET

    How in the world is Merck gonna rebrand a product it has spent so much time, effort and money gearing toward females so that males will use it, too? I'm not sure, but it'll be interesting to watch if or when MRK wins Food and Drug Administration approval of Gardasil for boys/young men.

  • Pharma And The Financial Crisis Thursday, 13 Nov 2008 | 11:11 AM ET
    Big Pharma

    Big pharma's got big problems. That should not come as news to anyone who works for, follows or invests in the industry.

  • "Boning Up" On Amgen's D-mab Friday, 7 Nov 2008 | 12:05 PM ET
    AMGEN

    While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.

  • FDA Commissioner: Betting Starts On Who Obama Will Pick Wednesday, 5 Nov 2008 | 12:20 PM ET
    Barack Obama

    Even before the results of the election were official there was already speculation in the blogosphere about who might become the next Commissioner of the Food and Drug Administration under a President Obama.

  • Athletes And The Weapons To Fight The "Superbug" Friday, 31 Oct 2008 | 1:24 PM ET

    I’m sure you’ve seen all the stories regarding athletes and staph infections more technically known as MRSA. Although the information each time has been sketchy, the names Kellen Winslow, Tom Brady and Peyton Manning have become associated with it in recent weeks.

  • Merck Shows "Sensitivity" Amid Massive Cuts Wednesday, 22 Oct 2008 | 10:56 AM ET
    Merck Earnings

    You gotta feel sorry for the folks at Merck. Immediately after the drugmaker finishes a program to get rid of more than 10,000 employees, the company drops the ax again.

  • Readers Make Me Take My Medicine Friday, 17 Oct 2008 | 5:06 PM ET

    As we head into the weekend (TGIF, right?), I wanted to clean out the ol' inbox.

  • Lilly In The "Pink"--But Then Again Not Friday, 17 Oct 2008 | 10:57 AM ET
    Effient Ad

    I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.

  • Genentech-A-Go-Go: Our Lips Are Sealed Wednesday, 15 Oct 2008 | 10:03 AM ET
    Genentech Earnings

    On the Genentech third quarter earnings conference call analysts, investors and reporters were hoping to get some color on the status of the Roche play for the rest of DNA it doesn't already own.

  • The Last Word--For Now--On Dendreon Wednesday, 8 Oct 2008 | 10:55 AM ET

    Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.

  • Roche Speaks My Language But Genentech Not So Much Tuesday, 7 Oct 2008 | 11:59 AM ET

    In my reporting, I always try to keep it simple. Particularly in the middle of the credit crisis, too much financial jargon goes over the heads of most people. The same can be said for biopharma coverage.

  • Could The Credit Crisis Help Pfizer? Monday, 6 Oct 2008 | 3:46 PM ET

    Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).

  • Biotech Bonanza For ImClone & Dendreon Monday, 6 Oct 2008 | 10:56 AM ET

    Okay, what were the chances that ImClone would get bought and Dendreon would come out with its interim test results on the same morning? Slim to none, I'd say. But that's exactly what the news gods had in store for two of the hottest names in biotech.

  • Dendreon, ImClone & Pfizer: Your Emails Friday, 3 Oct 2008 | 10:37 AM ET

    As all eyes remain on Capitol Hill, things remain relatively quiet on the biopharma front. So, it's a good time to go through the Pharma's Market mailbag. The overwhelming majority of emails recently have been about...yeah, you guessed it...Dendreon.

  • While the Street is focused on the big vote in the Senate tonight on the bailout package, biotech investors will be on the lookout for news out of ImClone Systems. Earlier this week the company announced that its mystery counter-bidder will decide whether to follow through on its $70-a-share offer by midnight tonight.

  • The Waiting Game Continues For Lilly & ImClone Monday, 29 Sep 2008 | 10:42 AM ET

    Eli Lilly has been running direct-to-doctor ads over the past few months telling physicians that Effient, the company's new bloodthinner, is "Coming Soon". Well, it may have jumped the gun.

  • Lilly

    Today is the day the FDA is expected to make a decision on the drug. The agency could approve it outright, approve it with conditions/limitations, delay making a decision--again--and order more tests, or reject the pill.

  • Mardi Gras Beads

    There are reports of booze, women and beads--as in Mardi Gras beads. Specifically, the piece cites allegations from a lawsuit brought by a former MDT attorney who says the medical device maker sponsored a "discussion group" outing to New Orleans.

  • As the press release that came with the book says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."